Trial | NCT02323893  Report issue

Title

Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans
Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG, a Positron Emission Tomography Tracer for Imaging the Activation of the Immune System in Healthy Humans

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    arag ...

  • Study Participants

    6
The goal of this study is to visualize biodistribution of a PET tracer called [18F]F-AraG through time in healthy human volunteers.
A positron emission tomography (PET) imaging tracer will be intravenously injected into healthy human volunteers who provide informed consent. Following injection of this tracer each volunteer will have four whole-body PET scans inside a PET scanner to obtain images of tracer biodistribution at four different time points. This will allow studying the kinetics of the tracer as well analysis of tracer dosimetry. Safety of the tracer will also be analyzed in each volunteer.
Study Started
Feb 28
2015
Primary Completion
Dec 31
2017
Study Completion
Dec 31
2017
Last Update
May 17
2018

Drug [18F]F-AraG

18F-FAraG Experimental

A single dose intravenous injection of 18F-FAraG followed by PET scanning.

Criteria 

Inclusion Criteria:

Healthy human subjects without history of chronic disease or at present an acute disease will be included.
Ability to abide by the study conditions is also a requirement for inclusion.

Exclusion Criteria:

Individuals under the age of 18 years and pregnant women will be excluded from the [18F]F-AraG imaging studies.
Women who are breast-feeding will be excluded from the study.
Individuals unable to provide informed consent will be excluded.
No Results Posted